Latest Cannabinoids News

Neurotech International has dosed the first patient in its pivotal Phase 3 Beyond Harmony study of NTI164, moving the autism therapy into its most consequential clinical test yet. The trial plans to enrol up to 200 children across six Australian sites, but no Phase 3 efficacy data are available at this stage.

Argent BioPharma has secured a key FDA regulatory milestone with the establishment of an Investigational New Animal Drug (INAD) file for its CannEpil veterinary program, targeting cancer-related pain in companion animals.

Argent BioPharma's licensing partner Splash Beverage Group has launched the US veterinary development program for CannEpil®, targeting companion-animal oncology and chronic pain. Led by industry veteran Dr Hunter Land, the initiative follows a defined FDA regulatory pathway and could broaden CannEpil®’s commercial footprint beyond human neurology.

Neurotech International has secured $4.5 million through a share placement to fund its pivotal Phase III clinical trial of NTI164 for Autism Spectrum Disorder, aiming to reach topline data readout.

Neurotech International has secured FDA clearance for its NTI164 Investigational New Drug application and obtained Notices of Allowance for two US patents, advancing its Phase 3 autism spectrum disorder program.

Zelira Therapeutics has raised nearly US$33 million into its HOPE® 1 special purpose vehicle, valuing the SPV at about US$66 million post-money. The funds will advance FDA regulatory submissions and Phase 1 clinical trials for its autism-targeting cannabinoid drug.

Argent BioPharma has eliminated US$5.5 million in secured debt through a global licensing agreement for its CannEpil® epilepsy therapy, while completing a key acquisition and advancing clinical trials in veterinary therapeutics.

ECS Botanics plans to introduce two 2g all-in-one vape products under its OzSun brand in mid-August 2026, expanding its higher-margin B2C portfolio with a capital-efficient supply model.

Neurotech International has secured FDA clearance for its Investigational New Drug application for NTI164, enabling clinical development in the US and advancing its global registration and commercialisation plans.

Neurotech International has received Notices of Allowance from the USPTO for two patents covering its lead drug NTI164, reinforcing its intellectual property position as it advances Phase 3 trials for autism spectrum disorder.

Neurotech International has opened its first Phase 3 clinical site for NTI164 targeting Autism Spectrum Disorder, reported positive 90-day toxicology results, and launched a new Rett syndrome research collaboration.

IDT Australia is poised for its strongest FY26 finish since its transformation began, forecasting a dramatic narrowing of EBITDA losses and revenue growth driven by strategic partnerships and operational upgrades.